Shares of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) have been assigned a consensus rating of “Hold” from the seven research firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $32.60.

Several brokerages have weighed in on EIGR. Zacks Investment Research raised Eiger BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a research note on Tuesday, June 6th. BTIG Research began coverage on Eiger BioPharmaceuticals in a research note on Friday, July 14th. They set a “buy” rating and a $32.00 target price on the stock. ValuEngine raised Eiger BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Oppenheimer Holdings, Inc. set a $34.00 target price on Eiger BioPharmaceuticals and gave the company a “buy” rating in a research note on Thursday, June 8th. Finally, Wedbush reaffirmed an “ourperform” rating and set a $34.00 target price on shares of Eiger BioPharmaceuticals in a research note on Monday, August 14th.

Shares of Eiger BioPharmaceuticals (NASDAQ EIGR) traded up 2.33% on Wednesday, reaching $11.00. The company had a trading volume of 26,828 shares. The stock has a 50 day moving average price of $8.93 and a 200-day moving average price of $8.60. The company’s market capitalization is $92.04 million. Eiger BioPharmaceuticals has a 12 month low of $6.10 and a 12 month high of $14.75.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last announced its earnings results on Monday, August 14th. The biotechnology company reported ($1.33) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.05). Analysts forecast that Eiger BioPharmaceuticals will post ($5.21) EPS for the current fiscal year.

In other news, Director Jeffrey S. Glenn acquired 15,000 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were bought at an average price of $9.53 per share, with a total value of $142,950.00. Following the purchase, the director now owns 31,355 shares of the company’s stock, valued at $298,813.15. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. 28.80% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Susquehanna International Group LLP bought a new stake in shares of Eiger BioPharmaceuticals in the 2nd quarter worth $114,000. Goldman Sachs Group Inc. bought a new stake in shares of Eiger BioPharmaceuticals in the 2nd quarter worth $272,000. Hikari Power Ltd raised its stake in shares of Eiger BioPharmaceuticals by 491.0% in the 2nd quarter. Hikari Power Ltd now owns 60,992 shares of the biotechnology company’s stock worth $482,000 after buying an additional 50,672 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Eiger BioPharmaceuticals by 6.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 14,567 shares of the biotechnology company’s stock worth $115,000 after buying an additional 871 shares in the last quarter. Finally, LMR Partners LLP bought a new stake in shares of Eiger BioPharmaceuticals in the 2nd quarter worth $116,000. 59.94% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Brokerages Set Eiger BioPharmaceuticals, Inc. (EIGR) PT at $32.60” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/30/brokerages-set-eiger-biopharmaceuticals-inc-eigr-pt-at-32-60.html.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Receive News & Stock Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.